Myriad: the oral arguments


On Monday, April 15, the US Supreme Court heard oral arguments on whether genetic material is patent eligible subject matter and in particular, whether Utah-based Myriad Genetics’ patents covering isolated human genes linked to breast and ovarian cancer are valid and enforceable.

Myriad, gene patents, US Supreme Court, oral arguments, BRCA1